{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:00:10Z","timestamp":1777917610475,"version":"3.51.4"},"reference-count":4,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliat Med"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>Levomepromazine (methotrimeprazine) is an anti-psychotic used at low dose for the control of nausea and vomiting. When levomepromazine hydrochloride as Nozinan\u00ae is diluted with 0.9% sodium chloride at concentrations ranging from 0.13 to 6.25\u2009mg\/ml, and stored in polypropylene syringes, the drug is stable for at least 14 days.<\/jats:p>","DOI":"10.1177\/0269216310387963","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T22:50:48Z","timestamp":1295477448000},"page":"284-285","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Is levomepromazine stable over time?"],"prefix":"10.1177","volume":"25","author":[{"given":"J","family":"Hardy","sequence":"first","affiliation":[{"name":"Department of Palliative and Supportive Care, Mater Health Services, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care, Mater Health Services, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mater Health Services, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Norris","sequence":"additional","affiliation":[{"name":"Australian Centre for Paediatric Pharmacokinetics, Mater Health Services, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"bibr1-0269216310387963","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0768-1"},{"key":"bibr2-0269216310387963","doi-asserted-by":"publisher","DOI":"10.1191\/0269216305pm972oa"},{"key":"bibr3-0269216310387963","volume-title":"The United States pharmacopeia","year":"2008","edition":"31"},{"key":"bibr4-0269216310387963","volume-title":"Handbook on Injectable Drugs","author":"Trissel LA","year":"2008","edition":"15"}],"container-title":["Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269216310387963","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269216310387963","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269216310387963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:18:13Z","timestamp":1777659493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269216310387963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":4,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1177\/0269216310387963"],"URL":"https:\/\/doi.org\/10.1177\/0269216310387963","relation":{},"ISSN":["0269-2163","1477-030X"],"issn-type":[{"value":"0269-2163","type":"print"},{"value":"1477-030X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}